Large real-world studies examining survival outcomes specifically for de novo metastatic HER2-positive breast cancer are lacking, despite this subtype typically having a better prognosis than recurrent metastatic HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.